Diabetic Retinopathy
Conditions
Interventions
Control Group:Basic Treatment
Treatment Group:Basic Treatmrnt + Mingmou Jianshen Paste Treatment
Sponsors
Jiangsu Province Hospital of Chinese Medicine/Affiliated Hospital of Nanjing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Patients with type 2 diabetes mellitus; confirmed by fundus photography or angiography as having non-proliferative diabetic retinopathy; aged 18-65 years; regardless of gender. (2) Absence of acute diabetic complications (e.g. diabetic ketoacidosis; non-ketotic hyperosmolar syndrome; etc.) and severe chronic complications (such as diabetic nephropathy with nephrotic syndrome; severe diabetic peripheral neuropathy; diabetic lower extremity arterial occlusion; etc.). (3) Fasting and postprandial blood glucose levels <16.7 mmol/L in the past 3 months; blood pressure =140/90 mmHg; and BMI =30 kg/m². (4) Signed written informed consent obtained. (5) Diagnosed by traditional Chinese medicine criteria as Qi-Yin deficiency with dampness and blood stasis obstructing the collaterals.
Exclusion criteria
Exclusion criteria: (1) Presence of other ocular conditions that may cause macular edema; such as retinal vein occlusion; uveitis; age-related macular degeneration; hypertensive retinopathy; significant cataracts affecting vision assessment; or glaucoma interfering with mydriatic examination. (This criterion excludes cases where such conditions are unilateral with the contralateral eye unaffected.) (2) Severe primary systemic disorders involving respiratory; circulatory; digestive; urinary; nervous; hematologic; rheumatic; or endocrine systems; including malignancies and AIDS. (3) Individuals with allergic predisposition or known hypersensitivity/intolerance to medications used in this study. (4) Pregnancy; lactation; psychiatric disorders; or any condition potentially compromising treatment compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diabetic retinopathy staging;ETDRS visual acuity score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Retinal thickness in the macular area;TCM sydrome score;serum PANoptosome-related molecular proteins; | — |
Countries
China
Contacts
Public ContactYue Zhao
Jiangsu Province Hospital of Chinese Medicine/Affiliated Hospital of Nanjing University of Chinese Medicine
Outcome results
None listed